<DOC>
	<DOCNO>NCT00182143</DOCNO>
	<brief_summary>The purpose study evaluate effect Low Molecular Weight Heparin ( LMWH ) ( Fragmin , dalteparin ) versus Unfractionated Heparin ( UFH ) primary outcome proximal leg Deep Vein Thrombosis ( DVT ) diagnose compression ultrasound , secondary outcome Pulmonary Embolism ( PE ) , bleed , Heparin-Induced Thrombocytopenia ( HIT ) , objectively confirm venous thrombosis site .</brief_summary>
	<brief_title>PROphylaxis ThromboEmbolism Critical Care Trial ( PROTECT )</brief_title>
	<detailed_description>PROTECT : The PROphylaxis ThromboEmbolism Critical Care Trial . Background : Critically ill patient increase risk deep venous thrombosis ( DVT ) due acute illness , procedures central venous catheterization , immobility . Among patient intensive care unit ( ICU ) , DVT important problem , since thrombus propagation embolization lead potentially fatal pulmonary embolism ( PE ) . Only 1 randomized trial ( n=119 ) medical-surgical ICU patient demonstrate unfractionated heparin ( UFH ) prevent DVT compare prophylaxis ; 1 randomize trial ( n=223 ) ventilate COPD patient show low molecular weight heparin ( LMWH ) prevent DVT compare prophylaxis . In medical-surgical ICUs , effect LMWH v UFH DVT prevention test . On one hand , LMWH likely effective venous thromboembolism ( VTE ) prevention associate low rate heparin-induced thrombocytopenia ( HIT ) . On hand , UFH likely associate less bleeding , less expensive . Current guideline indicate absence comparative data , LMWH UFH suitable thromboprophylaxis population , randomize trial need . PROTECT Pilot : In Pilot Study , feasibility objective ass : 1 ) timely enrolment complete , blind study drug administration , 2 ) bioaccumulation LMWH patient acquire renal insufficiency , 3 ) twice weekly leg ultrasound , 4 ) recruitment rate . 1 . Timely , complete administration occur 98 % scheduled dos ; every dose blind . 2 . No LWMH bioaccumulation observe . 3 . Scheduled ultrasound occur without exception . 4 . Recruitment 4 patients/month/centre modification 3 exclusion criterion PROTECT pilot . Objective : To evaluate effect LMWH ( dalteparin ) v UFH primary outcome proximal leg DVT diagnose compression ultrasound , secondary outcome PE , bleeding , HIT , objectively confirm venous thrombosis site . Design : Prospective randomize stratify conceal blind multicentre trial . Population : Inclusion Criteria : Eligible patient medical-surgical ICUs &gt; 18 year old , weigh &gt; 45 kg , expect ICU stay &gt; 72 hour . Exclusion Criteria : Patients admit ICU post trauma , orthopedic surgery , neurosurgery , severe hypertension , DVT , PE major hemorrhage within 3 month , International Normalized Ratio ( INR ) &gt; 2 ULN , Partial Thromboplastin Time ( PTT ) &gt; 2 ULN , platelets &lt; 75 x 109/L , require therapeutic anticoagulation exclude . Patients contraindication heparin , blood product pork product , &gt; 3 day LMWH UFH ICU , patient pregnant , undergo withdrawal life support , enrol related trial also exclude . Methods : Using centralize telephone randomization , allocate 3,650 patient 40 centre LMWH ( dalteparin ) 5,000 IU daily UFH 5,000 IU twice daily SC duration ICU stay . Patients , family , clinician researcher blind ; pharmacist aware allocation . Bilateral proximal leg compression ultrasound perform within 48h ICU admission , twice weekly , suspicion DVT . PE diagnose predefined diagnostic algorithm . We record bleed , HIT , venous thrombosis complication . Protocol adherence maximize use training , manual , study aid , site visit , audit feedback . Blinded Adjudication Committees adjudicate endpoint . PROTECT conduct Canadian Critical Care Trials Group overseen independent DSMB . Relevance : The result PROTECT use develop evidence base practice guideline regard safety efficacy LMWH ( dalteparin ) v UFH thromboprophylaxis medical-surgical ICU patient around world .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Patient &gt; /= 18 year age 2 . Actual body weight &gt; /= 45 kg 3 . Admission ICU expect &gt; /= 72 hour duration 1 . Neurosurgery within last 3 month 2 . Ischemic stroke within last 3 month 3 . Intracranial hemorrhage within last 3 month 4 . Systolic Blood Pressure &gt; /= 180mm Hg , Diastolic Blood Pressure &gt; /= 110mm Hg &gt; /= 12 hour require vasoactive drug infusion 5 . Major hemorrhage within last week unless definitively treat 6 . Coagulopathy define INR &gt; /= 2 time upper limit normal [ ULN ] , PTT &gt; /= 2 time ULN , time screen 7 . Thrombocytopenia define platelet count &lt; /= 75 x 109/L , time screen 8 . Other heparin contraindication ( e.g. , HIT , pregnancy , lactate ) 9 . Contraindication blood product ( e.g. , Jehovah 's Witness ) 10 . Unable perform lower limb ultrasound ( e.g. , bilateral knee amputation , severe distal extremity burn ) 11 . Limitation life support , Life expectancy &lt; /= 14 day , palliative care 12 . Contamination ( e.g. , &gt; /= 3 dos LMWH ICU admission ) 13 . Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Critically Ill</keyword>
	<keyword>Deep Venous ThromboEmbolism</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>